



## (Core Project R03OD030604)

### Overview

High-level info about this project.

| Projects        | Name   | Award  | Publications   | Repositories   | Analytics    |
|-----------------|--|--------|----------------|----------------|--------------|
| 1R03OD030604-01 | Using Common Fund data to inform rare disease preclinical models and prioritize drug repurposing | \$297K | 9 publications | 0 repositories | 0 properties |

## Publications

Published works associated with this project.


| ID   | Title  | Authors   | RC<br>R   | SJ<br>R   | Cita<br>tions | Cit./<br>yea<br>r | Journal                       | Publ<br>ishe<br>d | Upda<br>ted  |
|--|--|---|-----------|-----------|---------------|-------------------|-------------------------------|-------------------|--------------|
| <a href="#">35337371</a>    | Considerations and challenges for sex-aware drug repurposing.  | Fisher,<br>Jennifer L<br>...4<br>more...<br>Lasseigne,<br>Brittany<br>N | 1.3<br>66 | 1.7<br>99 | 16            | 5.33<br>3         | Biology of sex differences    | 2022              | Dec 28, 2025 |
| <a href="#">38167211</a>  | Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ... | Fisher,<br>Jennifer L<br>...2<br>more...<br>Lasseigne,<br>Brittany<br>N | 1.2<br>28 | 0.8<br>14 | 6             | 6                 | BMC pharmacology & toxicology | 2024              | Dec 28, 2025 |
| <a href="#">38531616</a>  | Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposi... | Fisher,<br>Jennifer L<br>...7<br>more...<br>Lasseigne                   | 0.8<br>12 | 0.8<br>57 | 3             | 3                 | FEBS open bio                 | 2024              | Dec 28, 2025 |

|  |  |   |           |           |   |     |  |                         |
|--|--|---|-----------|-----------|---|-----|--|-------------------------|
|  | e,<br>Brittany<br>N  |   |           |           |   |     |  |                         |
| <a href="#">37217845</a>    | Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and... | Wilk,<br>Elizabeth<br>J<br>...9<br>more...<br>Lasseigne,<br>e,<br>Brittany<br>N | 0.5<br>81 | 1.7<br>52 | 5 | 2.5 | Molecular<br>medicine<br>(Cambridge,<br>Mass.) | 2023 Dec<br>28,<br>2025 |
| <a href="#">37533331</a>    | Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease... | Williams,<br>Avery S<br>...2<br>more...<br>Lasseigne,<br>e,<br>Brittany<br>N    | 0.5<br>65 | 0.7<br>29 | 5 | 2.5 | Cancer reports<br>(Hoboken, N.J.)              | 2023 Dec<br>28,<br>2025 |
| <a href="#">36602970</a>  | Ten simple rules for using public biological data for your research.                                 | Oza,<br>Vishal H<br>...9<br>more...<br>Lasseigne,<br>e,<br>Brittany<br>N        | 0.3<br>64 | 1.5<br>03 | 3 | 1.5 | PLoS<br>computational<br>biology               | 2023 Dec<br>28,<br>2025 |

|                          |  |   |           |           |   |     |   |      |              |
|--------------------------|--|---|-----------|-----------|---|-----|---|------|--------------|
| <a href="#">37824797</a> | Computational Advancements in Cancer Combination Therapy Prediction.                                 | Flanary,<br>Victoria L<br>...3<br>more...<br>Lasseigne,<br>Brittany N | 0.2<br>96 | 2.4<br>09 | 3 | 1.5 | JCO precision oncology                    | 2023 | Dec 28, 2025 |
| <a href="#">37362157</a> | Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets ... | Fisher,<br>Jennifer L<br>...2<br>more...<br>Lasseigne,<br>Brittany N  | 0.1<br>7  | 0         | 1 | 0.5 | bioRxiv : the preprint server for biology | 2023 | Dec 28, 2025 |
| <a href="#">37090499</a> | Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-disease... | Williams,<br>Avery S<br>...2<br>more...<br>Lasseigne,<br>Brittany N   | 0         | 0         | 0 | 0   | bioRxiv : the preprint server for biology | 2023 | Dec 28, 2025 |

### Publications (cumulative)

Total: 9



## Notes

RCR [Relative Citation Ratio](#) ↗

SJR [Scimago Journal Rank](#) ↗

# </> Repositories

Software repositories associated with this project.

Built on Jan 16, 2026

Developed with support from NIH Award [U54 OD036472](#)

| N<br>a<br>m<br>e | Description | T<br>a<br>g<br>s | Last Commit | t<br>a<br>r<br>s | o<br>tc<br>h<br>k<br>s | a<br>m<br>m<br>e<br>it<br>rs<br>s | o<br>m<br>e<br>it<br>s | Issues | PRs | s<br>u<br>e<br>A<br>v<br>A<br>g | R<br>A<br>d<br>b<br>m<br>u<br>g | e<br>a<br>i<br>b<br>m<br>u<br>e<br>t<br>o<br>n<br>i<br>n<br>e | r<br>a<br>f<br>b<br>u<br>c<br>s<br>e<br>t<br>o<br>n<br>i<br>n<br>e | e<br>c<br>e<br>f<br>n<br>r<br>i<br>s<br>b<br>g<br>e<br>t<br>o<br>n<br>i<br>n<br>e | n<br>t<br>r<br>e<br>n<br>r<br>i<br>s<br>b<br>g<br>e<br>t<br>o<br>n<br>i<br>n<br>e | ..<br>g<br>u<br>a<br>g<br>e<br>s |
|------------------|-------------|------------------|-------------|------------------|------------------------|-----------------------------------|------------------------|--------|-----|---------------------------------|---------------------------------|---|--|---|---|----------------------------------|
|                  | No data     |                  |             |                  |                        |                                   |                        |        |     |                                 |                                 |   |  |   |   |                                  |

## Notes

Repository For storing, tracking changes to, and collaborating on a piece of software.

PR "Pull request", a draft change (new feature, bug fix, etc.) to a repo.

Closed/Open Resolved/unresolved.

Issue/PR Avg Average time issues/pull requests stay open for before being closed.

Only the main/default branch is considered for metrics like # of commits.

# of dependencies is totaled from all manifests in repo, direct and transitive, e.g. package.json + package-lock.json .

## Analytics

Website metrics associated with this project.

### Notes

Active Users [Distinct users who visited the website ↗](#).

New Users [Users who visited the website for the first time ↗](#).

Engaged Sessions [Visits that had significant interaction ↗](#).

"Top" metrics are measured by number of engaged sessions.